A Phase 1 interventional study of NDX-1017 and Placebo in Alzheimer Disease, sponsored by Athira Pharma. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-10.
Sponsored by Athira Pharma · Phase 1, Interventional, and Treatment
This Phase 1 randomized, placebo-controlled, double-blinded, first-in-human study will evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of NDX-1017 in healthy young and elderly subjects, and elderly subjects with amnestic mild cognitive impairment (MCI), Alzheimer's disease (mild, mild-to-moderate, or moderate), or mixed dementia with Alzheimer's and vascular components (mild, mild-to-moderate, or moderate).
NDX-1017 is being developed for the treatment of Alzheimer's disease (AD).
This Phase 1 randomized, placebo-controlled, double-blinded, first-in-human study will evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of NDX-1017 in healthy young and elderly subjects, and elderly subjects with mild AD. The study contains the following two parts:
Part A:
A single-ascending dose (SAD) study conducted in an inpatient setting for 3 days in healthy young male and healthy elderly male and female volunteers evaluated in up to 7 dose cohorts to identify the maximum tolerated dose (MTD) within the single dose range studied. Up to 56 subjects (aged 18 to 45 years for young and 60 to 85 years for elderly) may be enrolled in Part A.
Part B:
A multiple ascending dose (MAD) study conducted in an inpatient setting for 10 days in male or female healthy elderly volunteers (aged 60 to 85 years) or subjects with amnestic mild cognitive impairment (MCI), Alzheimer's disease (mild, mild-to-moderate, or moderate), or mixed dementia with Alzheimer's and vascular components (mild, mild-to-moderate, or moderate) (aged 40 to 85 years) in up to 6 dose cohorts that were proven tolerable in the SAD part of the study to identify the MTD within the multiple dose range studied. Up to 44 subjects (aged 40 to 85 years) may be enrolled in Part B.
Subjects will be screened for eligibility within 28 days (or 90 days for amnestic MCI, Alzheimer's Disease, or mixed dementia with Alzheimer's and vascular components) prior to enrollment. Those eligible will be admitted to an inpatient facility for investigational product administration, safety monitoring, and collection of blood or urine for pharmacokinetic evaluations.
[Amnestic MCI and Alzheimer's Subjects] 9. Patients with Alzheimer's disease, with confirmed diagnosis of amnestic mild cognitive impairment, Alzheimer's disease (mild, mild-to-moderate, or moderate), or mixed dementia with Alzheimer's and vascular components (mild, mild-to-moderate, or moderate).
EXCLUSION CRITERIA:
NDX-1017 will be administered via subcutaneous injection
Drug: NDX-1017
Placebo will be administered via subcutaneous injection
Drug: Placebo
Solution of NDX-1017 for subcutaneous injection
Placebo solution for subcutaneous injection
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability].
Safety and tolerability of single or multiple ascending doses of NDX-1017 as measured by vital signs and clinical laboratory measurements.
Time frame: Up to 20 days
Maximum observed plasma concentration (Cmax).
Cmax will be determined from all collected plasma samples from baseline through up to 48 hours post-dose.
Time frame: Samples collected at predetermined timepoints within 48 hours post-dose.
Time to maximum observed plasma concentration (Tmax).
Tmax will be determined from all collected plasma samples from baseline through up to 48 hours post-dose.
Time frame: Samples collected at predetermined timepoints within 48 hours post-dose.
Plasma concentration at the end of the dosing interval (Ctrough).
Ctrough will be determined from the last plasma sample prior to the following dose (MAD only).
Time frame: Samples collected at predetermined timepoints within 48 hours post-dose.
Area under the plasma concentration time curve (AUC).
AUC will be determined from all collected plasma samples from baseline through up to 48 hours post-dose.
Time frame: Samples collected at predetermined timepoints within 48 hours post-dose.
Half-life (t1/2).
t1/2 will be determined from all collected plasma samples from baseline through up to 48 hours post-dose.
Time frame: Samples collected at predetermined timepoints within 48 hours post-dose.
Plan to share: No
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Athira Pharma